{"id":7742,"date":"2025-04-10T09:05:59","date_gmt":"2025-04-10T09:05:59","guid":{"rendered":"https:\/\/tst.incliva.es\/?page_id=7742"},"modified":"2025-04-10T09:05:59","modified_gmt":"2025-04-10T09:05:59","slug":"juan-miguel-cejalvo-andujar","status":"publish","type":"page","link":"https:\/\/tst.incliva.es\/en\/juan-miguel-cejalvo-andujar\/","title":{"rendered":"Juan Miguel Cejalvo And\u00fajar"},"content":{"rendered":"<p><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container fusion-parallax-none nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: #ededed;background-image: url(&quot;https:\/\/www.incliva.es\/wp-content\/uploads\/2021\/01\/fondo.jpg&quot;);background-position: center center;background-repeat: no-repeat;border-width: 0px 0px 0px 0px;border-color:#e2e2e2;border-style:solid;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\">\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_3_4 3_4 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-text fusion-text-1\" style=\"transform:translate3d(0,0,0);\"><h3>Dr. Juan Miguel Cejalvo And\u00fajar<\/h3>\n<\/div>\n<div class=\"fusion-separator fusion-full-width-sep\" style=\"align-self: center;margin-left: auto;margin-right: auto;margin-bottom:3px;width:100%;\"><div class=\"fusion-separator-border sep-single sep-solid\" style=\"border-color:#9da0d2;border-top-width:1px;\"><\/div><\/div>\n<div class=\"fusion-text fusion-text-2\" style=\"transform:translate3d(0,0,0);\"><h5><span style=\"color: #3D44AC;\">Emerging Investigator<br \/>\nResearch Group on Breast Cancer Biology<br \/>\n<\/span><\/h5>\n<\/div>\n<div class=\"fusion-separator fusion-full-width-sep\" style=\"align-self: center;margin-left: auto;margin-right: auto;margin-bottom:10px;width:100%;\"><div class=\"fusion-separator-border sep-single sep-solid\" style=\"border-color:#9da0d2;border-top-width:1px;\"><\/div><\/div>\n<div class=\"fusion-text fusion-text-3\" style=\"transform:translate3d(0,0,0);\"><h4 style=\"text-align: justify;\">Presentation<\/h4>\n<\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-0{width:75% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-0 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 2.56%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 2.56%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-0{width:75% !important;}.fusion-builder-column-0 > .fusion-column-wrapper {margin-right : 2.56%;margin-left : 2.56%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-0{width:100% !important;}.fusion-builder-column-0 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-1 fusion_builder_column_1_4 1_4 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;background-color:#ffffff;border-width: 0 0 0 2px;border-color:#9da0d2;border-style:solid;padding: 4% 4% 4% 4%;\">\n<div ><span class=\" fusion-imageframe imageframe-none imageframe-1 hover-type-none\" style=\"border-radius:5px;\"><img src=\"\/wp-content\/uploads\/2025\/02\/Juan-Miguel-Cejalvo.jpg\" class=\"img-responsive\"\/><\/span><\/div>\n<div class=\"fusion-separator fusion-full-width-sep\" style=\"align-self: center;margin-left: auto;margin-right: auto;margin-top:10px;margin-bottom:10px;width:100%;\"><\/div>\n<div class=\"fusion-text fusion-text-4\" style=\"transform:translate3d(0,0,0);\"><h5 style=\"text-align: center;\">Emerging<br \/>\nInvestigator<\/h5>\n<div style=\"text-align: center;\">Dr. Juan Miguel Cejalvo And\u00fajar<\/div>\n<p style=\"text-align: center;\"><a href=\"mailto:juanmitch5@hotmail.com\">juanmitch5@hotmail.com<\/a><\/p>\n<\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-1{width:25% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-1 > .fusion-column-wrapper {padding-top : 4% !important;padding-right : 4% !important;margin-right : 7.68%;padding-bottom : 4% !important;padding-left : 4% !important;margin-left : 7.68%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-1{width:25% !important;order : 0;}.fusion-builder-column-1 > .fusion-column-wrapper {margin-right : 7.68%;margin-left : 7.68%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-1{width:100% !important;order : 0;}.fusion-builder-column-1 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<\/div>\n<style type=\"text\/css\">.fusion-fullwidth.fusion-builder-row-1 { overflow:visible; }.fusion-body .fusion-flex-container.fusion-builder-row-1{ padding-top : 2%;margin-top : 0px;padding-right : 0px;padding-bottom : 0px;margin-bottom : 0px;padding-left : 0px;}<\/style><\/div><br \/>\n<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-2 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: #e5e5e5;background-position: center center;background-repeat: no-repeat;border-width: 0px 0px 0px 0px;border-color:#e2e2e2;border-style:solid;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\">\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-2 fusion_builder_column_1_1 1_1 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-text fusion-text-5\" style=\"transform:translate3d(0,0,0);\"><h5>Publications<\/h5>\n<\/div>\n<div class=\"fusion-tabs fusion-tabs-1 classic horizontal-tabs icon-position-left\"><style type=\"text\/css\">.fusion-tabs.fusion-tabs-1 .nav-tabs li a.tab-link{border-top-color:#f9f9fb;background-color:#f9f9fb;}.fusion-tabs.fusion-tabs-1 .nav-tabs{background-color:#ffffff;}.fusion-tabs.fusion-tabs-1 .nav-tabs li.active a.tab-link,.fusion-tabs.fusion-tabs-1 .nav-tabs li.active a.tab-link:hover,.fusion-tabs.fusion-tabs-1 .nav-tabs li.active a.tab-link:focus{border-right-color:#ffffff;}.fusion-tabs.fusion-tabs-1 .nav-tabs li.active a.tab-link,.fusion-tabs.fusion-tabs-1 .nav-tabs li.active a.tab-link:hover,.fusion-tabs.fusion-tabs-1 .nav-tabs li.active a.tab-link:focus{background-color:#ffffff;}.fusion-tabs.fusion-tabs-1 .nav-tabs li a:hover{background-color:#ffffff;border-top-color:#ffffff;}.fusion-tabs.fusion-tabs-1 .tab-pane{background-color:#ffffff;}.fusion-tabs.fusion-tabs-1 .nav,.fusion-tabs.fusion-tabs-1 .nav-tabs,.fusion-tabs.fusion-tabs-1 .tab-content .tab-pane{border-color:#e2e2e2;}<\/style><div class=\"nav\"><ul class=\"nav-tabs nav-justified\" role=\"tablist\"><li class=\"active\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-3136b869043ad91b104\" aria-selected=\"true\" id=\"fusion-tab-2024\" href=\"#tab-3136b869043ad91b104\"><h4 class=\"fusion-tab-heading\">2024<\/h4><\/a><\/li><li><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-f9ca38031842df75eb1\" aria-selected=\"false\" tabindex=\"-1\" id=\"fusion-tab-2023\" href=\"#tab-f9ca38031842df75eb1\"><h4 class=\"fusion-tab-heading\">2023<\/h4><\/a><\/li><li><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-add4012cca1e465526e\" aria-selected=\"false\" tabindex=\"-1\" id=\"fusion-tab-2022\" href=\"#tab-add4012cca1e465526e\"><h4 class=\"fusion-tab-heading\">2022<\/h4><\/a><\/li><li><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-2a80f5a4ef7c6a50c45\" aria-selected=\"false\" tabindex=\"-1\" id=\"fusion-tab-2021\" href=\"#tab-2a80f5a4ef7c6a50c45\"><h4 class=\"fusion-tab-heading\">2021<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-content\"><div class=\"nav fusion-mobile-tab-nav\"><ul class=\"nav-tabs nav-justified\"><li class=\"active\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-3136b869043ad91b104\" aria-selected=\"true\" id=\"mobile-fusion-tab-2024\" href=\"#tab-3136b869043ad91b104\"><h4 class=\"fusion-tab-heading\">2024<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-pane fade fusion-clearfix in active\" role=\"tabpanel\" tabindex=\"0\" aria-labelledby=\"fusion-tab-2024\" id=\"tab-3136b869043ad91b104\">\n<div style=\"padding-top:4%;padding-left:4%; padding-right:4%; text-align:justify;\">\nNK cell-triggered CCL5\/IFNgamma-CXCL9\/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer. Santana-Hernandez S, Suarez-Olmos J, Servitja S, Berenguer-Molins P, Costa-Garcia M, Comerma L, Rea A, Perera-Bel J, Menendez S, Arpi O, Bermejo B, Martinez M, Cejalvo J, Comino-Mendez I, Pascual J, Alba E, Lopez-Botet M, Rojo F, Rovira A, Albanell J, Muntasell A. Journal of Experimental &#038; Clinical Cancer Research. 2024 Jan 3;43(1):10. doi: <a href='https:\/\/doi.org\/10.1186\/s13046-023-02918-4' target='_blank'>10.1186\/s13046-023-02918-4<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/38167224' target='_blank'>38167224<\/a><\/p>\n<\/div>\n<\/div><div class=\"nav fusion-mobile-tab-nav\"><ul class=\"nav-tabs nav-justified\"><li><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-f9ca38031842df75eb1\" aria-selected=\"false\" tabindex=\"-1\" id=\"mobile-fusion-tab-2023\" href=\"#tab-f9ca38031842df75eb1\"><h4 class=\"fusion-tab-heading\">2023<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-pane fade fusion-clearfix\" role=\"tabpanel\" tabindex=\"0\" aria-labelledby=\"fusion-tab-2023\" id=\"tab-f9ca38031842df75eb1\">\n<div style=\"padding-top:4%;padding-left:4%; padding-right:4%; text-align:justify;\">\nAuthor Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. Schettini F, Chic N, Bras\u00f3-Maristany F, Par\u00e9 L, Pascual T, Conte B, Mart\u00ednez-S\u00e1ez O, Adamo B, Vidal M, Barnadas E, Fern\u00e1ndez-Martinez A, Gonz\u00e1lez-Farre B, Sanfeliu E, Cejalvo JM, Perrone G, Sabarese G, Zalfa F, Peg V, Fasani R, Villagrasa P, Gavil\u00e1 J, Barrios CH, Lluch A, Mart\u00edn M, Locci M, De Placido S, Prat A. NPJ Breast Cancer. 2023 Apr 29;9(1):32. doi: <a href='https:\/\/doi.org\/10.1038\/s41523-023-00538-x' target='_blank'>10.1038\/s41523-023-00538-x<\/a>. Erratum for: NPJ Breast Cancer. 2021 Jan 4;7(1):1. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37120452' target='_blank'>37120452<\/a><\/p>\n<p>AXL &#8211; a new player in resistance to HER2 blockade. Adam-Artigues A, Arenas E, Arribas J, Prat A, Cejalvo J. Cancer Treatment Reviews. 2023 Dec:121:102639. doi: <a href='https:\/\/doi.org\/10.1016\/j.ctrv.2023.102639' target='_blank'>10.1016\/j.ctrv.2023.102639<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37864955' target='_blank'>37864955<\/a><\/p>\n<p>Delivery of miR-200c-3p using tumor-targeted mesoporous silica nanoparticles for breast cancer therapy. Garrido-Cano I, Adam-Artigues A, Lameirinhas A, Blandez J, Candela-Noguera V, Lluch A, Bermejo B, Sancenon F, Cejalvo J, Martinez-Manez R, Eroles P. ACS Applied Materials &#038; Interfaces. 2023 Aug 16;15(32):38323-38334. doi: <a href='https:\/\/doi.org\/10.1021\/acsami.3c07541' target='_blank'>10.1021\/acsami.3c07541<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37549382' target='_blank'>37549382<\/a><\/p>\n<p>High VEGFR3 expression reduces doxorubicin efficacy in triple-negative breast cancer. Torres Ruiz S, Tormo E, Garrido Cano I, Lameirinhas A, Rojo F, Madoz Gurpide J, Burgues O, Hernando C, Bermejo B, Martinez MT, Lluch A, Cejalvo JM, Eroles P. International Journal of Molecular Sciences. 2023 Feb 10;24(4):3601. doi: <a href='https:\/\/doi.org\/10.3390\/ijms24043601' target='_blank'>10.3390\/ijms24043601<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36835014' target='_blank'>36835014<\/a><\/p>\n<p>HOPE (SOLTI-1903) breast cancer study: real-world, patient-centric, clinical practice study to assess the impact of genomic data on next treatment decision-choice in patients with locally advanced or metastatic breast cancer. Olivera-Salguero R, Segui E, Cejalvo J, Oliveira M, Tolosa P, Vidal M, Malumbres M, Gavila J, Saura C, Pernas S, Lopez R, Margeli M, Balmana J, Munoz M, Blancas I, Boni V, Ciruelos E, Galve E, Perello A, Sanchez-Bayona R, de la Cruz S, de la Hoya M, Galvan P, Sanfeliu E, Gonzalez-Farre B, Sirenko V, Blanch-Torras A, Canes J, Masanas H, Olmos R, Forns M, Prat A, Casas A, Pascual T. Frontiers in Oncology. 2023 Apr 28;13:1151496. doi: <a href='https:\/\/doi.org\/10.3389\/fonc.2023.1151496' target='_blank'>10.3389\/fonc.2023.1151496<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37188177' target='_blank'>37188177<\/a><\/p>\n<style type=\"text\/css\">.fusion-accordian  #accordion-7742-1 .panel-title a .fa-fusion-box{ color: #ffffff;}.fusion-accordian  #accordion-7742-1 .panel-title a .fa-fusion-box:before{ font-size: 14px; width: 14px;}.fusion-accordian  #accordion-7742-1.fusion-toggle-icon-right .fusion-toggle-heading{ margin-right: 32px;}.fusion-accordian  #accordion-7742-1 .panel-title a{font-size:14px;}.fusion-accordian  #accordion-7742-1 .fa-fusion-box { background-color: #212934;border-color: #212934;}.fusion-accordian  #accordion-7742-1 .panel-title a:hover, #accordion-7742-1 .fusion-toggle-boxed-mode:hover .panel-title a { color: #3bafbf;}.fusion-accordian  #accordion-7742-1 .panel-title .active .fa-fusion-box,.fusion-accordian  #accordion-7742-1 .panel-title a:hover .fa-fusion-box { background-color: #3bafbf!important;border-color: #3bafbf!important;}<\/style><div class=\"accordian fusion-accordian\"><div class=\"panel-group fusion-toggle-icon-right\" id=\"accordion-7742-1\" role=\"tablist\">\n<div class=\"fusion-panel panel-default\" role=\"tabpanel\"><div class=\"panel-heading\"><h4 class=\"panel-title toggle\"><a aria-expanded=\"false\" aria-selected=\"false\" aria-controls=\"e44b56c557c13d328\" role=\"tab\" data-toggle=\"collapse\" data-parent=\"#accordion-7742-1\" data-target=\"#e44b56c557c13d328\" href=\"#e44b56c557c13d328\"><span class=\"fusion-toggle-icon-wrapper\" aria-hidden=\"true\"><i class=\"fa-fusion-box\" aria-hidden=\"true\"><\/i><\/span><span class=\"fusion-toggle-heading\">More publications from 2023<\/span><\/a><\/h4><\/div><div id=\"e44b56c557c13d328\" class=\"panel-collapse collapse \"><div class=\"panel-body toggle-content fusion-clearfix\">\nIn the Literature: january 2023. Martin-Arana J, Gambardella V, Tarazona N, Cejalvo JM, Cervantes A. ESMO Open. 2023 Jan 3;8(1):100763. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2022.100763' target='_blank'>10.1016\/j.esmoop.2022.100763<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36603523' target='_blank'>36603523<\/a><\/p>\n<p>In the literature: May 2023. Gambardella V, Cejalvo J, Cervantes A. ESMO Open. 2023 May 15;8(3):101562. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2023.101562' target='_blank'>10.1016\/j.esmoop.2023.101562<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37196398' target='_blank'>37196398<\/a><\/p>\n<p>miR-146a-5p promotes angiogenesis and confers trastuzumab resistance in HER2+ breast cancer. Cabello P, Torres-Ruiz S, Adam-Artigues A, Fores-Martos J, Martinez M, Hernando C, Zazo S, Madoz-Gurpide J, Rovira A, Burgues O, Rojo F, Albanell J, Lluch A, Bermejo B, Cejalvo J, Eroles P. Cancers. 2023 Apr 4;15(7):2138. doi: <a href='https:\/\/doi.org\/10.3390\/cancers15072138' target='_blank'>10.3390\/cancers15072138<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37046799' target='_blank'>37046799<\/a><\/p>\n<p>Nodal positivity and systemic therapy among patients with clinical T1-T2N0 human epidermal growth factor receptor-positive breast cancer: Results from two international cohorts. Weiss A, Martinez-Saez O, Waks A, Laws A, McGrath M, Tarantino P, Portnow L, Winer E, Rey M, Tapia M, Prat A, Partridge A, Tolaney S, Cejalvo J, Mittendorf E, King T. Cancer. 2023 Jun 15;129(12):1836-1845. doi: <a href='https:\/\/doi.org\/10.1002\/cncr.34750' target='_blank'>10.1002\/cncr.34750<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36951169' target='_blank'>36951169<\/a><\/p>\n<p>Patritumab deruxtecan in untreated hormone receptor-positive\/HER2-negativeearly breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study. Oliveira M, Falato C, Cejalvo J, Vila M, Tolosa P, Salvador-Bofill F, Cruz J, Arumi M, Luna A, Guerra J, Vidal M, Martinez-Saez O, Pare L, Gonzalez-Farre B, Sanfeliu E, Ciruelos E, Espinosa-Bravo M, Pernas S, Izarzugaza Y, Esker S, Fan P, Parul P, Santhanagopal A, Sellami D, Villacampa G, Ferrero-Cafiero J, Pascual T, Prat A. Annals of Oncology. 2023 Aug;34(8):670-680. doi: <a href='https:\/\/doi.org\/10.1016\/j.annonc.2023.05.004' target='_blank'>10.1016\/j.annonc.2023.05.004<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37211044' target='_blank'>37211044<\/a><\/p>\n<p>Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH Trial. Perez-Garcia J, Batista M, Cortez P, Ruiz-Borrego M, Cejalvo J, de la Haba-Rodriguez J, Garrigos L, Racca F, Servitja S, Blanch S, Gion M, Nave M, Fernandez-Abad M, Martinez-Bueno A, Llombart-Cussac A, Sampayo-Cordero M, Malfettone A, Cortes J, Braga S. Neuro-Oncology. 2023 Jan 5;25(1):157-166. doi: <a href='https:\/\/doi.org\/10.1093\/neuonc\/noac144' target='_blank'>10.1093\/neuonc\/noac144<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35639825' target='_blank'>35639825<\/a><\/p>\n<p>Triple negative PAM50 non-basal breast cancer subtype predicts benefit from extended adjuvant capecitabine. Asleh K, Lluch A, Goytain A, Barrios C, Wang X, Torrecillas L, Gao D, Ruiz-Borrego M, Leung S, Bines J, Guerrero-Zotano A, Garcia-Saenz J, Cejalvo J, Herranz J, Torres R, de la Haba-Rodriguez J, Ayala F, Gomez H, Rojo F, Nielsen T, Martin M. Clinical Cancer Research. 2023 Jan 17;29(2):389-400. doi: <a href='https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2191' target='_blank'>10.1158\/1078-0432.CCR-22-2191<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36346687' target='_blank'>36346687<\/a><\/p>\n<\/div><\/div><\/div>\n<\/div><\/div><\/div>\n<\/div><div class=\"nav fusion-mobile-tab-nav\"><ul class=\"nav-tabs nav-justified\"><li><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-add4012cca1e465526e\" aria-selected=\"false\" tabindex=\"-1\" id=\"mobile-fusion-tab-2022\" href=\"#tab-add4012cca1e465526e\"><h4 class=\"fusion-tab-heading\">2022<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-pane fade fusion-clearfix\" role=\"tabpanel\" tabindex=\"0\" aria-labelledby=\"fusion-tab-2022\" id=\"tab-add4012cca1e465526e\">\n<div style=\"padding-top:4%;padding-left:4%; padding-right:4%; text-align:justify;\">\nImmunological landscape of HER-2 positive breast cancer. Moragon S, Hernando C, Martinez-Martinez M, Tapia M, Ortega-Morillo B, Lluch A, Bermejo B, Cejalvo J. Cancers. 2022 Jun 28;14(13):3167. doi: <a href='https:\/\/doi.org\/10.3390\/cancers14133167' target='_blank'>10.3390\/cancers14133167<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35804943' target='_blank'>35804943<\/a><\/p>\n<p>In the literature: February 2022. Gambardella V, Cejalvo JM, Gonzalez Barrallo I, Gimeno Valiente F, Cervantes A. ESMO open. 2022 Feb 23;7(2):100411. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2022.100411' target='_blank'>10.1016\/j.esmoop.2022.100411<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35219243' target='_blank'>35219243<\/a><\/p>\n<p>In the literature: November 2022. Gambardella V, Cejalvo J, Cervantes A. ESMO Open. 2022 Nov 17;7(6):100643. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2022.100643' target='_blank'>10.1016\/j.esmoop.2022.100643<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36403559' target='_blank'>36403559<\/a><\/p>\n<p>LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer. Perez-Nunez I, Rozalen C, Palomeque J, Sangrador I, Dalmau M, Comerma L, Hernandez-Prat A, Casadevall D, Menendez S, Liu D, Shen M, Berenguer J, Ruiz I, Pena R, Montanes J, Alba M, Bonnin S, Ponomarenko J, Gomis R, Cejalvo J, Servitja S, Marzese D, Morey L, Voorwerk L, Arribas J, Bermejo B, Kok M, Pusztai L, Kang Y, Albanell J, Celia-Terrassa T. Nature Cancer. 2022 Mar;3(3):355-370. doi: <a href='https:\/\/doi.org\/10.1038\/s43018-022-00339-4' target='_blank'>10.1038\/s43018-022-00339-4<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35301507' target='_blank'>35301507<\/a><\/p>\n<p>miR-99a-5p modulates doxorubicin resistance via the COX-2\/ABCG2 axis in triple-negative breast cancer: from the discovery to in vivo studies. Garrido-Cano I, Adam-Artigues A, Lameirinhas A, Blandez J, Candela-Noguera V, Rojo F, Zazo S, Madoz-Gurpide J, Lluch A, Bermejo B, Sancenon F, Cejalvo J, Martinez-Manez R, Eroles P. Cancer Communications. 2022 Dec;42(12):1412-1416. doi: <a href='https:\/\/doi.org\/10.1002\/cac2.12352' target='_blank'>10.1002\/cac2.12352<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35997029' target='_blank'>35997029<\/a><\/p>\n<style type=\"text\/css\">.fusion-accordian  #accordion-7742-2 .panel-title a .fa-fusion-box{ color: #ffffff;}.fusion-accordian  #accordion-7742-2 .panel-title a .fa-fusion-box:before{ font-size: 14px; width: 14px;}.fusion-accordian  #accordion-7742-2.fusion-toggle-icon-right .fusion-toggle-heading{ margin-right: 32px;}.fusion-accordian  #accordion-7742-2 .panel-title a{font-size:14px;}.fusion-accordian  #accordion-7742-2 .fa-fusion-box { background-color: #212934;border-color: #212934;}.fusion-accordian  #accordion-7742-2 .panel-title a:hover, #accordion-7742-2 .fusion-toggle-boxed-mode:hover .panel-title a { color: #3bafbf;}.fusion-accordian  #accordion-7742-2 .panel-title .active .fa-fusion-box,.fusion-accordian  #accordion-7742-2 .panel-title a:hover .fa-fusion-box { background-color: #3bafbf!important;border-color: #3bafbf!important;}<\/style><div class=\"accordian fusion-accordian\"><div class=\"panel-group fusion-toggle-icon-right\" id=\"accordion-7742-2\" role=\"tablist\">\n<div class=\"fusion-panel panel-default\" role=\"tabpanel\"><div class=\"panel-heading\"><h4 class=\"panel-title toggle\"><a aria-expanded=\"false\" aria-selected=\"false\" aria-controls=\"da1a7f9b1b414eb78\" role=\"tab\" data-toggle=\"collapse\" data-parent=\"#accordion-7742-2\" data-target=\"#da1a7f9b1b414eb78\" href=\"#da1a7f9b1b414eb78\"><span class=\"fusion-toggle-icon-wrapper\" aria-hidden=\"true\"><i class=\"fa-fusion-box\" aria-hidden=\"true\"><\/i><\/span><span class=\"fusion-toggle-heading\">More publications from 2022<\/span><\/a><\/h4><\/div><div id=\"da1a7f9b1b414eb78\" class=\"panel-collapse collapse \"><div class=\"panel-body toggle-content fusion-clearfix\">\nmTOR inhibition and trastuzumab-emtansine (T-DM1) in HER2-positive breast cancer. Casadevall D, Hernandez-Prat A, Garc A-Alonso S, Arpi-Llucia O, Menendez S, Qin M, Guardia C, Morancho B, Sanchez-Mart N F, Zazo S, Gavilan E, Sabbaghi M, Eroles P, Cejalvo J, Lluch A, Rojo F, Pandiella A, Rovira A, Albanell J. Molecular Cancer Research. 2022 Jul 6;20(7):1108-1121. doi: <a href='https:\/\/doi.org\/10.1158\/1541-7786.MCR-21-0545' target='_blank'>10.1158\/1541-7786.MCR-21-0545<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35348729' target='_blank'>35348729<\/a><\/p>\n<p>Oncolytic viruses: a new immunotherapeutic approach for breast cancer treatment?. Cejalvo JM, Falato C, Villanueva L, Tolosa P, Gonzalez X, Pascal M, Canes J, Gavila J, Manso L, Pascual T, Prat A, Salvador F. Cancer Treatment Reviews. 2022 May;106:102392. doi: <a href='https:\/\/doi.org\/10.1016\/j.ctrv.2022.102392' target='_blank'>10.1016\/j.ctrv.2022.102392<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35436729' target='_blank'>35436729<\/a><\/p>\n<p>Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A. Mouron S, Bueno MJ, Lluch A, Manso L, Calvo I, Cortes J, Garcia-Saenz JA, Gil-Gil M, Martinez-Janez N, Apala JV, Caleiras E, Xim\u00e9nez-Emb\u00fan P, Mu\u00f1oz J, Gonzalez-Cortijo L, Murillo R, S\u00e1nchez-Bayona R, Cejalvo JM, G\u00f3mez-L\u00f3pez G, Fustero-Torre C, Sabroso-Lasa S, Malats N, Martinez M, Moreno A, Megias D, Malumbres M, Colomer R, Quintela-Fandino M. Nature Communications. 2022 Dec 7;13(1):7529. doi: <a href='https:\/\/doi.org\/10.1038\/s41467-022-35065-z' target='_blank'>10.1038\/s41467-022-35065-z<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36477027' target='_blank'>36477027<\/a><\/p>\n<p>SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA. Prat A, Paz-Ares L, Juan M, Felip E, Garralda E, Gonzalez B, Arance A, Martin-Liberal J, Gavila J, Lopez-Gonzalez A, Miguel Cejalvo J, Izarzugaza Y, Amillano K, Garcia Corbacho J, Saura C, Racca F, Hierro C, Sanfeliu E, Gonzalez X, Canes J, Villacampa G, Salvador F, Pascual T, Mesia R, Cervantes A, Tabernero J. Future Oncology. 2022 Oct 6. doi: <a href='https:\/\/doi.org\/10.2217\/fon-2022-0660' target='_blank'>10.2217\/fon-2022-0660<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36200668' target='_blank'>36200668<\/a><\/p>\n<p>Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer. Adam-Artigues A, Arenas E, Martinez-Sabadell A, Braso-Maristany F, Cervera R, Tormo E, Hernando C, Martinez M, Carbonell-Asins J, Simon S, Poveda J, Moragon S, Zazo S, Martinez D, Rovira A, Burgues O, Rojo F, Albanell J, Bermejo B, Lluch A, Prat A, Arribas J, Eroles P, Cejalvo J. Science Advances. 2022 May 20;8(20):eabk2746. doi: <a href='https:\/\/doi.org\/10.1126\/sciadv.abk2746' target='_blank'>10.1126\/sciadv.abk2746<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35594351' target='_blank'>35594351<\/a><\/p>\n<\/div><\/div><\/div>\n<\/div><\/div><\/div>\n<\/div><div class=\"nav fusion-mobile-tab-nav\"><ul class=\"nav-tabs nav-justified\"><li><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-2a80f5a4ef7c6a50c45\" aria-selected=\"false\" tabindex=\"-1\" id=\"mobile-fusion-tab-2021\" href=\"#tab-2a80f5a4ef7c6a50c45\"><h4 class=\"fusion-tab-heading\">2021<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-pane fade fusion-clearfix\" role=\"tabpanel\" tabindex=\"0\" aria-labelledby=\"fusion-tab-2021\" id=\"tab-2a80f5a4ef7c6a50c45\">\n<div style=\"padding-top:4%;padding-left:4%; padding-right:4%; text-align:justify;\">\nCirculating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancer. Adam-Artigues A, Garrido-Cano I, Simon S, Ortega B, Moragon S, Lameirinhas A, Constancio V, Salta S, Burgues O, Bermejo B, Henrique R, Lluch A, Jeronimo C, Eroles P, Cejalvo J. ESMO Open. 2021 Jan 18;6(1):100039. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2020.100039' target='_blank'>10.1016\/j.esmoop.2020.100039<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33477007' target='_blank'>33477007<\/a><\/p>\n<p>Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. Schettini F, Chic N, Braso-Maristany F, Pare L, Pascual T, Conte B, Martinez-Saez O, Adamo B, Vidal M, Barnadas E, Fernandez-Martinez A, Gonzalez-Farre B, Sanfeliu E, Cejalvo J, Perrone G, Sabarese G, Zalfa F, Peg V, Fasani R, Villagrasa P, Gavila J, Barrios C, Lluch A, Martin M, Locci M, De Placido S, Prat A. NPJ Breast Cancer. 2021 Jan 4;7(1):1. doi: <a href='https:\/\/doi.org\/10.1038\/s41523-020-00208-2' target='_blank'>10.1038\/s41523-020-00208-2<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33397968' target='_blank'>33397968<\/a><\/p>\n<p>Fertility and breast cancer: a literature review of counseling, preservation options and outcomes. Moragon S, Di Liello R, Bermejo B, Hernando C, Olcina E, Chirivella I, Lluch A, Cejalvo JM, Martinez MT, Critical Reviews In Oncology\/Hematology. 2021 Aug 27;166:103461. doi: <a href='https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103461' target='_blank'>10.1016\/j.critrevonc.2021.103461<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34461268' target='_blank'>34461268<\/a><\/p>\n<p>First nationwide molecular screening program in Spain for patients with advanced breast cancer: results from the AGATA SOLTI-1301 Study. Pernas S, Villagrasa P, Vivancos A, Scaltriti M, Rodon J, Burgues O, Nuciforo P, Canes J, Pare L, Duenas M, Vidal M, Cejalvo J, Perello A, Llommbard-Cussac A, Dorca J, Montano A, Pascual T, Oliveira M, Ribas G, Rapado I, Prat A, Ciruelos E. Frontiers in Oncology. 2021 Nov 4;11:744112. doi: <a href='https:\/\/doi.org\/10.3389\/fonc.2021.744112' target='_blank'>10.3389\/fonc.2021.744112<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34804931' target='_blank'>34804931<\/a><\/p>\n<p>In the literature: April 2021. Martin-Martorell P, Gonzalez-Barrallo I, Gambardella V, Cejalvo J M, Cervantes A. ESMO open. 2021 Apr 19;6(3):100116. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2021.100116' target='_blank'>10.1016\/j.esmoop.2021.100116<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33887688' target='_blank'>33887688<\/a><\/p>\n<style type=\"text\/css\">.fusion-accordian  #accordion-7742-3 .panel-title a .fa-fusion-box{ color: #ffffff;}.fusion-accordian  #accordion-7742-3 .panel-title a .fa-fusion-box:before{ font-size: 14px; width: 14px;}.fusion-accordian  #accordion-7742-3.fusion-toggle-icon-right .fusion-toggle-heading{ margin-right: 32px;}.fusion-accordian  #accordion-7742-3 .panel-title a{font-size:14px;}.fusion-accordian  #accordion-7742-3 .fa-fusion-box { background-color: #212934;border-color: #212934;}.fusion-accordian  #accordion-7742-3 .panel-title a:hover, #accordion-7742-3 .fusion-toggle-boxed-mode:hover .panel-title a { color: #3bafbf;}.fusion-accordian  #accordion-7742-3 .panel-title .active .fa-fusion-box,.fusion-accordian  #accordion-7742-3 .panel-title a:hover .fa-fusion-box { background-color: #3bafbf!important;border-color: #3bafbf!important;}<\/style><div class=\"accordian fusion-accordian\"><div class=\"panel-group fusion-toggle-icon-right\" id=\"accordion-7742-3\" role=\"tablist\">\n<div class=\"fusion-panel panel-default\" role=\"tabpanel\"><div class=\"panel-heading\"><h4 class=\"panel-title toggle\"><a aria-expanded=\"false\" aria-selected=\"false\" aria-controls=\"77fb01764c5c39a96\" role=\"tab\" data-toggle=\"collapse\" data-parent=\"#accordion-7742-3\" data-target=\"#77fb01764c5c39a96\" href=\"#77fb01764c5c39a96\"><span class=\"fusion-toggle-icon-wrapper\" aria-hidden=\"true\"><i class=\"fa-fusion-box\" aria-hidden=\"true\"><\/i><\/span><span class=\"fusion-toggle-heading\">More publications from 2021<\/span><\/a><\/h4><\/div><div id=\"77fb01764c5c39a96\" class=\"panel-collapse collapse \"><div class=\"panel-body toggle-content fusion-clearfix\">\nIn the literature: August 2021. Gambardella V, Alfaro-Cervello C, Cejalvo J, Tapia M, Cervantes A. ESMO Open. 2021 Aug 16;6(5):100247. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2021.100247' target='_blank'>10.1016\/j.esmoop.2021.100247<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34411970' target='_blank'>34411970<\/a><\/p>\n<p>In the literature: February 2021. Cejalvo J, Gambardella V, Fleitas T, Cervantes A. ESMO Open. 2021 Feb 24;6(2):100061. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2021.100061' target='_blank'>10.1016\/j.esmoop.2021.100061<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33639602' target='_blank'>33639602<\/a><\/p>\n<p>In the literature: June 2021. Gambardella V, Candia L, Tapia M, Cejalvo JM, Cervantes A. ESMO open. 2021 Jun;6(3):100186. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2021.100186' target='_blank'>10.1016\/j.esmoop.2021.100186<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34098228' target='_blank'>34098228<\/a><\/p>\n<p>Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study. Gambardella V, Lombardi P, Carbonell-Asins JA, Tarazona N, Cejalvo JM, Gonzalez-Barrallo I, Martin-Arana J, Tebar-Martinez R, Viala A, Bruixola G, Hernando C, Blasco I, Papaccio F, Martinez-Ciarpaglini C, Alfaro-Cervello C, Seda-Garcia E, Blesa S, Chirivella I, Castillo J, Monton-Bueno JV, Rosello S, Huerta M, Perez-Fidalgo A, Martin-Martorell P, Insa-Molla A, Fleitas T, Rentero-Garrido P, Zuniga-Trejos S, Cervantes A, Roda D. British Journal of Cancer. 2021 Oct;125(9):1261-1269. doi: <a href='https:\/\/doi.org\/10.1038\/s41416-021-01502-x' target='_blank'>10.1038\/s41416-021-01502-x<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34493820' target='_blank'>34493820<\/a><\/p>\n<p>Nanoporous Anodic Alumina-Based Sensor for miR-99a-5p Detection as an Effective Early Breast Cancer Diagnostic Tool. Garrido-Cano I, Pla L, Santiago-Felipe S, Simon S, Ortega B, Bermejo B, Lluch A, Cejalvo J, Eroles P, Martinez-Manez R. ACS Sensors. 2021 Mar 26;6(3):1022-1029. doi: <a href='https:\/\/doi.org\/10.1021\/acssensors.0c02222' target='_blank'>10.1021\/acssensors.0c02222<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33599490' target='_blank'>33599490<\/a><\/p>\n<p>Oral Selective Estrogen Receptor Degraders (SERDs) as a novel breast cancer therapy: present and future from a clinical perspective. Hernando C, Ortega-Morillo B, Tapia M, Moragon S, Martinez M, Eroles P, Garrido-Cano I, Adam-Artigues A, Lluch A, Bermejo B, Cejalvo J. International Journal of Molecular Sciences. 2021 Jul 22;22(15):7812. doi: <a href='https:\/\/doi.org\/10.3390\/ijms22157812' target='_blank'>10.3390\/ijms22157812<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34360578' target='_blank'>34360578<\/a><\/p>\n<p>SOLTI-1805 TOT-HER3 study concept: a window-of-opportunity trial of patritumab deruxtecan, a her3 directed antibody drug conjugate, in patients with early breast cancer. Pascual T, Oliveira M, Ciruelos E, Ezquerra M, Saura C, Gavila J, Pernas S, Munoz M, Vidal M, Vila M, Cejalvo J, Gonzalez-Farre B, Espinosa-Bravo M, Cruz J, Salvador-Bofill F, Guerra J, Barrera A, de Dios M, Esker S, Fan P, Martinez-Saez O, Villacampa G, Pare L, Ferrero-Cafiero J, Villagrasa P, Prat A. Frontiers in Oncology. 2021 Apr 23;11:638482. doi: <a href='https:\/\/doi.org\/10.3389\/fonc.2021.638482' target='_blank'>10.3389\/fonc.2021.638482<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33968735' target='_blank'>33968735<\/a><\/p>\n<\/div><\/div><\/div>\n<\/div><\/div><\/div>\n<\/div><\/div><\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-2{width:100% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-2 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 1.92%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 1.92%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-2{width:100% !important;}.fusion-builder-column-2 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-2{width:100% !important;}.fusion-builder-column-2 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<\/div>\n<style type=\"text\/css\">.fusion-body .fusion-flex-container.fusion-builder-row-2{ padding-top : 2%;margin-top : 0px;padding-right : 0px;padding-bottom : 0px;margin-bottom : 0px;padding-left : 0px;}<\/style><\/div><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-3 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: #e5e5e5;background-position: center center;background-repeat: no-repeat;border-width: 0px 0px 0px 0px;border-color:#e2e2e2;border-style:solid;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\">\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-3 fusion_builder_column_1_1 1_1 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-text fusion-text-6\" style=\"transform:translate3d(0,0,0);\"><h5>+ Info<\/h5>\n<\/div>\n<div class=\"fusion-tabs fusion-tabs-2 classic horizontal-tabs icon-position-left\"><style type=\"text\/css\">.fusion-tabs.fusion-tabs-2 .nav-tabs li a.tab-link{border-top-color:#f9f9fb;background-color:#f9f9fb;}.fusion-tabs.fusion-tabs-2 .nav-tabs{background-color:#ffffff;}.fusion-tabs.fusion-tabs-2 .nav-tabs li.active a.tab-link,.fusion-tabs.fusion-tabs-2 .nav-tabs li.active a.tab-link:hover,.fusion-tabs.fusion-tabs-2 .nav-tabs li.active a.tab-link:focus{border-right-color:#ffffff;}.fusion-tabs.fusion-tabs-2 .nav-tabs li.active a.tab-link,.fusion-tabs.fusion-tabs-2 .nav-tabs li.active a.tab-link:hover,.fusion-tabs.fusion-tabs-2 .nav-tabs li.active a.tab-link:focus{background-color:#ffffff;}.fusion-tabs.fusion-tabs-2 .nav-tabs li a:hover{background-color:#ffffff;border-top-color:#ffffff;}.fusion-tabs.fusion-tabs-2 .tab-pane{background-color:#ffffff;}.fusion-tabs.fusion-tabs-2 .nav,.fusion-tabs.fusion-tabs-2 .nav-tabs,.fusion-tabs.fusion-tabs-2 .tab-content .tab-pane{border-color:#e2e2e2;}<\/style><div class=\"nav\"><ul class=\"nav-tabs nav-justified\" role=\"tablist\"><li class=\"active\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-06c059d4b0d6379c670\" aria-selected=\"true\" id=\"fusion-tab-thesis\" href=\"#tab-06c059d4b0d6379c670\"><h4 class=\"fusion-tab-heading\">THESIS<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-content\"><div class=\"nav fusion-mobile-tab-nav\"><ul class=\"nav-tabs nav-justified\"><li class=\"active\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-06c059d4b0d6379c670\" aria-selected=\"true\" id=\"mobile-fusion-tab-thesis\" href=\"#tab-06c059d4b0d6379c670\"><h4 class=\"fusion-tab-heading\">THESIS<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-pane fade fusion-clearfix in active\" role=\"tabpanel\" tabindex=\"0\" aria-labelledby=\"fusion-tab-thesis\" id=\"tab-06c059d4b0d6379c670\"><span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Involvement of EZH2-MYC loop and SALL4 in epithelial-mesenchymal transition (EMT) and trastuzumab resistance process in HER2+ breast cancer<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Doctoral candidate: <\/span>Pattanayak Pattanayak, Chaudhuri Birlipta<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Director(s): <\/span>Eroles Asensio, Pilar; Cejalvo And\u00fajar, Juan Miguel<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Date of the defense: <\/span>26\/02\/2021<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">University: <\/span>Universitat de Val\u00e8ncia<\/p>\n<p><span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Uncovering the molecular and cellular mechanisms of metastatic dormancy in luminal breast cancer<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Doctoral candidate: <\/span>Cejalvo And\u00fajar, Juan Miguel<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Director(s): <\/span>Gomis Cabr\u00e9, Roger; Prat Aparicio, Aleix; Palac\u00edn Prieto, Manuel<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Date of the defense: <\/span>22\/01\/2020<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">University: <\/span>University de Barcelona<\/p>\n<\/div><\/div><\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-3{width:100% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-3 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 1.92%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 1.92%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-3{width:100% !important;order : 0;}.fusion-builder-column-3 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-3{width:100% !important;order : 0;}.fusion-builder-column-3 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<\/div>\n<style type=\"text\/css\">.fusion-body .fusion-flex-container.fusion-builder-row-3{ padding-top : 2%;margin-top : 0px;padding-right : 0px;padding-bottom : 0px;margin-bottom : 0px;padding-left : 0px;}<\/style><\/div><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"100-width.php","meta":[],"acf":[],"_links":{"self":[{"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/pages\/7742"}],"collection":[{"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/comments?post=7742"}],"version-history":[{"count":0,"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/pages\/7742\/revisions"}],"wp:attachment":[{"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/media?parent=7742"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}